Read More

Silvaco Analysts Recommend The Stock As Unique Small-Cap Opportunity In Semiconductor Design

Silvaco initiated with Buy rating and $26 price target by Rosenblatt analyst, well-positioned to benefit from EDA market with strong TCAD position and growth opportunities. Needham analyst also gives Buy rating and $28 target, forecasts improved margins and revenue.

CDNS

Read More

Toast Is a Dominant Player With Impressive Momentum, Says Analyst

Wedbush analyst Moshe Katri initiated coverage on Toast with an outperform rating and a $30 price target. Toast reported Q1 revenue of $1.075 billion, surpassing estimates. For 2024, adjusted EBITDA is expected between $250 million and $270 million. The analyst highlighted Toast's robust U.S. SMB pipeline and international market traction, projecting over 30% Y/Y growth in gross profit and EBITDA for FY24 and FY25.

TOST

Read More

AbbVie Is ‘Successfully Positioned To Absorb Humira Biosimilar Erosion’: Analyst

Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine, and achieve a high single-digit CAGR from 2024 to 2029.

ABBV